Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03468309 · ClinicalTrials.gov registry record
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
A clinical trial of Pharmacogenetic Testing, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT03468309 is a study of Pharmacogenetic Testing that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 53 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03468309, a study of Pharmacogenetic Testing, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to specific medication based on genetic markers. Thus, this study is a 12-week open-label, naturalistic study of the provision of pharmacogenetic testing and a computerized decision tool for providers to determine the potential efficacy of the assay to reduce polypharmacy and improve patient outcomes.
Conditions Studied
Interventions
- GENETIC Genecept Assay and G-DIG decision tool
Study Locations (1)
Washington
- VA Puget Sound Health Care System - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2024-04-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03468309
The ClinicalTrials.gov registry entry for NCT03468309 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacogenetic Testing appearing as the primary indexed condition, and to 1 intervention - of which Genecept Assay and G-DIG decision tool is the first listed.
NCT03468309 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03468309 about?
NCT03468309 is a clinical study titled "Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population". Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to ...
What is the current status of trial NCT03468309?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2018-01-01. Estimated completion is 2024-04-17.
What conditions does trial NCT03468309 study?
This clinical trial studies the following conditions: Pharmacogenetic Testing.
What interventions are being tested in trial NCT03468309?
The interventions under investigation include: Genecept Assay and G-DIG decision tool (GENETIC).
Who is sponsoring clinical trial NCT03468309?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03468309 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.